27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Of 22,025,599 individuals screened, 2,051,275 were eligible; matched cohorts ranged from 10,113 to 857,773, with median follow-up of 4.7 to 7.2 years. 5 key findings →
Design: cohort study Evidence: high
Full summary, score breakdown and related studies → Original source
Activities of daily living (ADLs) provide important indicators of functional decline in people living with dementia, motivating the need for continuous in-home monitoring. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
The high incidence of new prescribing, as well as the lack of deprescribing, points to unmet needs and a role for more proactive medication review. 3 key findings →
Participants: 3,713 Evidence: low
Full summary, score breakdown and related studies → Original source
Large language models (LLMs) offer new opportunities to synthesize the vast and heterogeneous biomedical literature, yet their potential to support drug target prioritization in complex diseases such as Alzheimer’s disease (AD) remains largely unexplored. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
A RAG-based LLM pipeline without structured ICD codes improved dementia ascertainment from EHR data compared with ICD-based rules and keyword-based filtering. 4 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
EOD incidence peaked at 4-5% among beneficiaries with and without cancer. 2 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Dementia risk may be increased among people with HIV with certain cancers, including AIDS-defining cancers. 1 key finding →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
The prevalence of dementia and Parkinson’s disease in Russia varies widely depending on diagnostic method, age group, and study design. 2 key findings →
Design: meta-analysis Participants: 20 Evidence: high
Full summary, score breakdown and related studies → Original source
Engaging 55 research staff across 25 sites and 3 physician-reviewers, this study is the first to demonstrate feasibility of a VANE as an efficient neurological examination model enabled by commonly used devices. 2 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Parkinson’s disease (PD) progression is highly heterogeneous. 2 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
The MCI group had the most surprising findings—although they were cognitively similar to the control group, they were less physically active than the AD group and had the worst sleep efficiency. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The mean age was 66.8 years and 21% had CI. 5 key findings →
Participants: 787 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Alzheimer’s disease (AD) is increasing in prevalence, and early detection is essential for timely care. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Spontaneous speech acoustics capture p-tau217/APOE-defined AD risk despite preserved cognition, supporting speech as a scalable, biologically grounded biomarker for preclinical AD risk stratification. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
In cognitively unimpaired older adults, associations between sleep disturbances and psycho-affective symptoms differ according to Aβ status. 2 key findings →
Design: cross-sectional Participants: 131 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Dementia is a major global health challenge; however, current diagnostic approaches often rely on invasive or costly procedures. 3 key findings →
Design: cross-sectional Participants: 88 Evidence: moderate
Full summary, score breakdown and related studies → Original source
We identified 27 phenotypes associated with APOE, mainly in neurological and lipid-related traits. 5 key findings →
Participants: 181,880 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Late-onset unexplained epilepsy is a potential harbinger of dementia, likely driven by network hyperexcitability that facilitates amyloid-β release and tau propagation. 3 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Parkinson’s disease (PD) exhibits considerable variability in symptom onset, severity, and clinical trajectories, making prediction of individual disease progression a complex challenge. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Performance variability precedes measurable linear decline across PD-risk stratified groups. 4 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
These findings identify an anatomically specific age-related profile of the human BF, with structural vulnerability manifest and pre-diagnostic neurological disorders, which is not substantially explained by common inherited risk. 2 key findings →
Design: cross-sectional Evidence: moderate
Full summary, score breakdown and related studies → Original source
The MoE-derived DNN-IR index demonstrated robust and stable performance in predicting atherosclerosis, incident CVD, cardiovascular mortality, and all-cause mortality in the general population. 3 key findings →
Design: cross-sectional Evidence: moderate
Full summary, score breakdown and related studies → Original source
DNA cytosine modifications play a crucial role in gene regulation that underlies the pathogenesis of complex diseases such as Alzheimer’s disease (AD). 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Longitudinal clinical cohorts contain heterogeneous progression patterns that are obscured by coarse diagnostic labels. 2 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Retirement timing alone showed limited association with later-life dementia risk, whereas sustained part-time employment and disability-related trajectories were more strongly associated with dementia risk. 5 key findings →
Participants: 13,879 Evidence: low
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →